Follow us on




Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Prototype devices

It is recognized that a manufacturer may wish to submit a small number  of "prototype models" of a device to clinical investigation in order to assess safety and/or performance; and those such prototypes may need to undergo a number of changes prior to large-scale production.

 Forums
Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :US-FDA Draft Guidance Recommends DSMBs, CECs for Heart Valve Studies.. 2010-01-21 19:22:51 
GCP HelpDesk
Moderator
Joined: 2009-06-18 15:31:58
Posts: 62
Location

Dear Friends,

The FDA recommended both Data Safety Monitoring Boards (DSMB) and Clinical Events Committees (CEC) be used for clinical trials examining replacement heart valves, in a draft guidance  issued Jan. 20. Click here for the Draft Guidance


The DSMB should establish criteria for recommending study termination for safety reasons before the study begins and should meet at least twice during the study to monitor adverse events, the agency recommended. The FDA said the DSMB should have members who are independent of the study sponsors and investigators and that two or more members should be physicians, including a cardiothoracic surgeon and a cardiologist. In addition, if the study includes statistical analyses, one DSMB member should be a statistician.


The Clinical Events Committee would adjudicate whether adverse events are valve-related and classify the severity of adverse events. Its members also should be independent of the study sponsors and investigators.


The guidance recommended that all study subjects be followed for at least one year. “If your clinical investigation is for one valve position, we recommend that you follow 300 or more subjects for one year or more for a total of 800 patient-years of follow-up.” If the study is for two valve positions, the agency recommended following 150 subjects for one year or more for each valve position for a total of 400 patient-years of follow-up per valve position.


The guidance said that “follow-up data should be collected for each subject until the entire study is terminated for all subjects.” The agency noted that as this follow-up period may be “significantly” longer than what is stated in the study protocol, and that the investigator must receive informed consent to such follow-up periods from all subjects.

Kind regards,

 

IP Logged
GCP HelpDesk
Page # 


Powered by ccBoard